From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

The University of Glasgow's Living Laboratory for Precision Medicine and myDNA, a leader in precision health, have announced a new partnership to generate evidence supporting the adoption of ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

Spruce Biosciences (SPRB) announced the company’s new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy for ...

After dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the rare genetic neurodegenerative ...

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for ...

One of the keys to BioMarin's success is that it focuses on orphan-disease therapies. This is a fancy way of saying it develops novel drugs to treat conditions that affect relatively small groups of ...